Results from a Phase 3 trial (NCT06143878) evaluating JNJ-77242113 for moderate to severe plaque psoriasis, which included deucravacitinib as a comparator, were posted on 2026-06-25. The study showed that JNJ-77242113 achieved an Investigator's Global Assessment (IGA) score of 0 or 1 and a >= 2-grade improvement from baseline in 68.5% of participants at Week 16, compared to 10.9% for placebo.
Background
The trial investigated treatments for moderate to severe plaque psoriasis, a chronic inflammatory skin condition. Deucravacitinib was included as a comparator intervention in this study.
Trial design
This was a Phase 3 trial (NCT06143878) titled "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". The study enrolled 774 participants with moderate to severe plaque psoriasis. The trial's purpose was to evaluate the effectiveness of JNJ-77242113 compared to placebo and deucravacitinib. Interventions included JNJ-77242113, JNJ-77242113 matching placebo, deucravacitinib, and deucravacitinib matching placebo.
Key results
The trial reported key measurements and analyses for participants receiving JNJ-77242113 200 mg compared to placebo:
- At Week 16, 68.5% of participants treated with JNJ-77242113 200 mg achieved an Investigator's Global Assessment (IGA) score of 0 or 1 and a >= 2-grade improvement from baseline, compared to 10.9% for placebo. The treatment difference was 57.6% (95.0% CI: 49.9%, 64.2%; p=0.001).
- At Week 16, 55.0% of participants treated with JNJ-77242113 200 mg achieved Psoriasis Area and Severity Index (PASI) 90, compared to 3.8% for placebo. The treatment difference was 51.2% (95.0% CI: 44.5%, 57.3%; p=0.001).
- At Week 16, 36.7% of participants treated with JNJ-77242113 200 mg achieved an IGA score of 0, compared to 1.9% for placebo. The treatment difference was 34.8% (95.0% CI: 28.7%, 40.7%; p=0.001).
- At Week 4, 12.2% of participants treated with JNJ-77242113 200 mg achieved PASI 75, compared to 2.6% for placebo. The treatment difference was 9.6% (95.0% CI: 4.8%, 14.3%; p=0.001).
- At Week 16, 74.3% of participants treated with JNJ-77242113 200 mg achieved PASI 75, compared to 11.5% for placebo. The treatment difference was 62.7% (95.0% CI: 55.1%, 69.1%; p=0.001).
- At Week 8, 19.9% of participants treated with JNJ-77242113 200 mg achieved PASI 90, compared to 1.3% for placebo. The treatment difference was 18.6% (95.0% CI: 13.5%, 23.5%; p=0.001).
What this means
The posted results indicate that JNJ-77242113 demonstrated significant efficacy in treating moderate to severe plaque psoriasis, achieving high rates of skin clearance as measured by IGA and PASI scores compared to placebo. For instance, the substantial difference in IGA 0/1 response at Week 16 (68.5% vs 10.9%) and PASI 75 response at Week 16 (74.3% vs 11.5%) highlights its potential in this indication. The trial included deucravacitinib as a comparator, though specific outcome measurements for deucravacitinib versus JNJ-77242113 or placebo were not detailed in the posted results.
Source
The trial results were posted on 2026-06-25 on ClinicalTrials.gov, an official database of clinical studies. The full details are available on clinicaltrials.gov under the identifier NCT06143878.